Physician profile
Patrick J Edwards
NPI 1851351191
$351.03
in general payments reported to CMS, 2019-2025
12 companies · $78.30 in 2025
The $78.30 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.42 · 2020: $30.84 · 2021: $24.59 · 2023: $36.24 · 2024: $169 · 2025: $78.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $283.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $96.68 | 2024-2025 | |
| Novo Nordisk INC | $51.13 | 2024-2025 | Wegovy |
| Amgen INC. | $37.03 | 2024 | Repatha, Otezla |
| Madrigal Pharmaceuticals | $26.04 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.59 | 2021 | |
| Daiichi Sankyo INC. | $22.49 | 2024 | Injectafer |
| Pfizer INC. | $19.85 | 2023 | |
| Lilly USA, LLC | $17.94 | 2020 | |
| Mylan Specialty L.P. | $16.39 | 2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.57 | 2024 | Caplyta |
| Glaxosmithkline, LLC. | $12.90 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.